コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 urface (10.3% of the imaging area in vehicle-treated animals).
2 reased survival to 30 d (vs. 9 d for vehicle-treated animals).
3 n all infected animals, except dexamethasone-treated animals.
4 ease in proteinuria was reduced in UK-396082-treated animals.
5 recovery compared with media- or fibroblast-treated animals.
6 0.0178) at 6 months of age compared to mock-treated animals.
7 ese changes were absent in the dexamethasone-treated animals.
8 single pegIFNalpha injection in only half of treated animals.
9 ctivated in the extraction wounds of the ALN-treated animals.
10 axons only in the spinal cord dorsal horn of treated animals.
11 fundus red reflex was only found among PF-MC treated animals.
12 nd regeneration scores decreased in Imm-124E treated animals.
13 r were observed in the remote region of cell-treated animals.
14 animals; which were absent in dexamethasone-treated animals.
15 -5 and (18)F-FDG uptake ratios versus saline-treated animals.
16 living animal, was significantly reduced in treated animals.
17 t an enrichment of sCSCs relative to control-treated animals.
18 eriodontal healing process compared with non-treated animals.
19 ation in infected lung tissues for linezolid-treated animals.
20 have been reported to accumulate in hair of treated animals.
21 6 survived significantly longer than control-treated animals.
22 eceptor were also increased in the PVN of E2 treated animals.
23 ed by immunohistochemistry for PAS-YNSalpha8-treated animals.
24 engraftment improved by several-fold in ETN-treated animals.
25 s postinjury, compared with control (LV-GFP)-treated animals.
26 ith insignificant differences relative to NS-treated animals.
27 nimals were compared to single mTBI and sham treated animals.
28 rats (left uninflated) compared with vehicle-treated animals.
29 itors significantly decreased weight loss in treated animals.
30 e was also significantly reduced in antibody-treated animals.
31 ymph node cells fell significantly in FTY720-treated animals.
32 s were upregulated in the PVN and RVLM of E2 treated animals.
33 in both the 810- and 532-nm micropulse laser-treated animals.
34 sone, respectively, in comparison to placebo treated animals.
35 still induced strong responses in the toxin-treated animals.
36 ed animals after 6 weeks relative to vehicle-treated animals.
37 rneal sensitivity and tear secretion in NPD1-treated animals.
38 irculating tumor-specific CD8 T cells in all treated animals.
39 The effect was similar to PEDF+DHA-treated animals.
40 C) were decreased 22- and 457-fold in MnTBAP-treated animals.
41 the Morris water maze as compared to vehicle-treated animals.
42 L fluid compared with values seen in vehicle-treated animals.
43 on significantly improved median survival of treated animals.
44 readily to the brain microvasculature in Tat treated animals.
45 with the islets of Langerhans in clorgyline-treated animals.
46 es, but completely inhibited in the morphine-treated animals.
47 lves latently infected with BHV-1 versus DEX-treated animals.
48 NA 5 days after Tx compared with the placebo-treated animals.
49 tricular function was maintained in MGCD0103-treated animals.
50 were significantly attenuated in resveratrol-treated animals.
51 al lymphatic vessel density reduced in SK1-I-treated animals.
52 with minimal islet pathology in nondiabetic treated animals.
53 robed with sera from either control or laser-treated animals.
54 ion of the radiopharmaceutical in clorgyline-treated animals.
55 nd trkB was elevated in the striatum in MDMA-treated animals.
56 lity, resulting in 100% survival of infected treated animals.
57 itubular capillaritis), were less in the TLN-treated animals.
58 e and were compared with age-matched vehicle-treated animals.
59 nd CD68(+) cells in anti-Netrin-1/anti-Unc5b-treated animals.
60 ithin 7 days compared with 14 days in saline-treated animals.
61 meters more severe in recipients of contrast-treated animals.
62 models classified the two groups control and treated animals.
63 mic viral RNA was detected in two out of six treated animals.
64 follicular helper (Tfh) cells, in belatacept-treated animals.
65 ansfer of control gut bacteria to antibiotic-treated animals.
66 ion in TNF-alpha with respect to non-SET-M33-treated animals.
67 igher regulatory T cell frequencies in FR104-treated animals.
68 e in osteoclasts in anti-Netrin-1/anti-Unc5b-treated animals.
69 cytes was increased in CBSC- versus vehicle- treated animals.
70 19, were both elevated in skin from contrast-treated animals.
71 c, was diminished in DRGs of all natalizumab-treated animals.
72 profound extension of the median survival of treated animals.
73 ration and was continued for 13 weeks in all treated animals.
74 ally cued navigation, when compared with PBS-treated animals.
75 trated elevated levels in the blood of FR104-treated animals.
76 ence in ox-LDL clearance was observed in NAC-treated animals.
77 rating complete responses in the majority of treated animals.
78 CD4(+) T cells recovered from VIPR2 agonist-treated animals.
79 l-treated animals but impairments in vehicle-treated animals.
80 is revealed insignificant changes in the DMA-treated animals.
81 were no erosions in anti-Netrin-1/anti-Unc5b-treated-animals.
82 eated, but not in cardiac-derived stem cells-treated, animals.
84 (-457 +/- 152 cells/muL) compared with 5C8H1-treated animals (16 +/- 25, P = 0.037), and the resurgen
85 responders and 3 nonresponders among the 10 treated animals); (2) recognize, for each individual sam
86 Isogenic and allogenic transplanted vehicle-treated animals (24/168 hr) and native gut served as con
88 odulatory subsystem connectivity in ketamine-treated animals, a finding consistent with the known eff
90 mor volume and increased cell death in ErPC3-treated animals accompanied by infiltration of the tumor
92 ster concentrations were lower in WIN 18,446-treated animals, adipose retinyl ester levels were incre
93 esponse to challenge was reduced in antibody-treated animals after 6 weeks relative to vehicle-treate
95 , and KLCD150(+)CD48(-) cells from IFN-gamma-treated animals all showed significant upregulation in F
96 ess were all increased in skin from contrast-treated animals-all parameters more severe in recipients
100 ber of neovascular tufts compared to vehicle-treated animals and a significant amount of normal blood
101 esensitization is indeed present in morphine-treated animals and is distinguished from cellular toler
102 nificantly, tumour growth was impaired in C4-treated animals and vascular density was also reduced in
103 rease in muscle strength was detected in all treated animals and was accompanied by a significant dec
106 Visual function was partially restored in treated animals, as evidenced by two visual behavioral t
107 ession was suppressed by 65-92% in capsaicin-treated animals, as was epinephrine (74%), norepinephrin
109 treated animals compared to SLPI and buffer-treated animals at 18 hours and 24 hours postinjury.
110 was observed in the plasma of 67% of the ART-treated animals at 7 weeks after ART interruption, and n
112 icantly different between rGDF11 and vehicle-treated animals at baseline and remained unchanged at 1,
113 ificant difference between drug- and vehicle-treated animals at day 3 for animals bearing U87-MG tumo
114 ls reject the graft, the transplants of 4C12-treated animals beat strongly and showed increased accum
116 ing, memory and mood function in resveratrol-treated animals but impairments in vehicle-treated anima
118 togenic T(E/M) cells remained present in the treated animals but showed increased expression of the i
120 ly in mutation induction in the germ line of treated animals, but also in altered mutation rates in t
121 ecombinant tissue-type plasminogen activator-treated animals, but enduring high thrombus activity in
122 the incidence of BE and EAC was decreased in treated animals by 35.7% (relative risk reduction, 36%;
123 rapidly reversed fatal liver failure in CCl4-treated animals by restoring diseased hepatocytes rather
125 antibiotics residues that are excreted from treated animals can contribute to persistence of resista
127 icant improvements in rotarod performance in treated animals compared to AAV2.9-MCK-eGFP-treated mice
128 veloped faster in paclitaxel and vincristine treated animals compared to cisplatin and bortezomib tre
129 were not significantly enhanced in the bnAb-treated animals compared to control animals, arguing aga
130 nd BWT scores were noted in CT images of MSC-treated animals compared to placebo-treated cats at mont
131 erated area was significantly lower in PF-MC treated animals compared to SLPI and buffer-treated anim
132 of pulmonary CD8(+) T lymphocytes in rhIL-7-treated animals compared to those in untreated mice.
133 to detect preserved systolic function in EHM-treated animals compared with control (control 4.4+/-1.0
135 vity were significantly increased in ethanol-treated animals compared with controls in the at-risk my
136 was achieved in the lipopolysaccharide (LPS)-treated animals compared with healthy controls (p<0.001)
139 progressive loss of dopaminergic neurons in treated animals compared with the control counterparts.
140 tion of IFN-stimulated genes in the blood of treated animals, confirming the reagent's bioactivity.
150 hout, the D2/D3 receptor availability of MPH-treated animals did not continue to decline at the same
151 In contrast to untreated, infected macaques, treated animals did not develop breathing abnormalities
153 ecombinant nematode anticoagulant protein c2-treated animals did not influence either fibrinolysis (a
156 lls isolated from anti-CD4 versus control Ab-treated animals displayed increased in vitro chemotaxis
158 o University of Wisconsin-treated and saline-treated animals, especially in skin and muscle when CI t
159 in antibody-treated than in control antibody-treated animals, even though IFN-gamma and NOS2 mRNA lev
164 At 2 and 4 weeks after injury, Ad-p27-126TS-treated animals exhibited reduced restenosis, complete r
167 ical effects were observed in glucocorticoid-treated animals following heterotopic (hepatic) expressi
170 urthermore, two weeks post-injury, PGI-02776-treated animals had a significant decrease in latency to
172 is revealed that clopidogrel- and ticagrelor-treated animals had a significantly smaller extent of MI
179 ogy, blood chemistry and coagulopathy, siRNA-treated animals had milder clinical features and fully r
181 Compared with untreated animals, UK-396082-treated animals had reduced glomerular and tubulointerst
186 and metastasis in contrast to MSCs- and MSC2-treated animals in which tumor growth and spread was inc
188 lasma cytokines were also attenuated in IL-6-treated animals, including significant reductions in TNF
189 did not occur in control or (177)Lu-DOTATATE-treated animals, including those where the primary tumor
191 rove episodic spatial memory relative to oil-treated animals, indicating closing of the critical wind
193 stance emergence was assessed in oseltamivir-treated animals infected with wild-type virus; emergence
194 production was increased in the pancreata of treated animals, insulin expression was strongly reduced
195 w the improved phenotype of the Cu(II)(atsm)-treated animals involves an increase in mature mutant SO
200 , in another study, that all of the antibody-treated animals lived, whereas 3/8 phosphate-buffered sa
201 wed prolonged survival compared with placebo-treated animals (mean+/-SEM, 24+/-9.3 vs. 5.4+/-3 days),
202 age resulted in hyperglycemia in only 20% of treated animals (n = 20) compared with 80% of controls (
205 ry and lasted approximately 1 week in 90% of treated animals (n=10, p<0.05), and all wounds were able
206 In contrast, in methadone- or buprenorphine-treated animals no respiratory depression was observed w
209 significantly different between control and treated animals over time in the region of low stress.
212 n control animals compared to RvD2- and RvD1-treated animals (P < 0.05), resulting in a reduction of
215 y, residual disease severity in the CD20 mAb-treated animals positively correlated with the frequency
217 sside-enhanced cardiopulmonary resuscitation-treated animals received sodium nitroprusside (2 mg) aft
220 were reduced by ca 40% in tumours from MM41-treated animals relative to controls, consistent with BC
221 nol than saline-treated subjects and ethanol-treated animals resilient to this form of behavioral pla
223 epress respiration but in prolonged morphine-treated animals respiratory depression was observed when
225 Th17 cells in the lamina propria of ITF2357-treated animals, resulting in the amelioration of diseas
226 nges in brain volumes normalized, whereas Li-treated animals retained significantly greater total bra
228 myelinated sciatic nerves from pioglitazone-treated animals revealed an unanticipated increase in ge
230 of mRNA expression and protein levels in ESA-treated animals revealed reduced matrix metalloproteinas
231 biofilm-infected tissues from MPhi- and EP67-treated animals, revealing effective reprogramming of th
234 bens (NAc) following CPP expression, cocaine treated animals showed increased phosphorylated ERK (pER
236 After 6 weeks of treatment, anti-TSLPR mAb-treated animals showed reduced bronchoalveolar lavage (B
240 d complement-mediated bacteriolysis, whereas treated animals showed slightly improved bacterial clear
241 lls from PF-06747143-treated or IgG1 control-treated animals showed that leukemic progenitors were al
243 body therapy, administered to two previously treated animals, successfully controlled virus rebound.
244 tion was enhanced by P-gp inhibitors in APAP-treated animals, suggesting P-gp-mediated transport.
245 y increased in hypocretin neurons in cocaine-treated animals, suggesting that CREB-mediated pathways
246 and decreased neurological deficit scores in treated animals, supporting the next preclinical studies
249 on in axon arbor complexity seen in d-serine-treated animals, tectal neuron visual receptive fields w
254 (11)C-PK11195 was elevated in dexamethasone-treated animals that had shown mild clinical symptoms th
255 is occurred also in lipopolysaccharide (LPS)-treated animals that mimic inflammation, as well as afte
258 nfiltration in the periodontium than vehicle-treated animals; these actions were associated with redu
260 r 80 mg/kg ketamine and compared with saline-treated animals to determine the effects of ketamine on
261 increased ART-related toxicity, causing all treated animals to succumb to acute pancreatitis and hyp
262 educed TTc in the spinal cord at 7 weeks for treated animals versus controls (5.2 Arbitrary Units +/-
264 sis in activated CD4(+) T cells, and renders treated animals vulnerable to TB reactivation and reinfe
266 ds, and the rate of cell engraftment in hCMP-treated animals was 24.5% at week 1 and 11.2% at week 4.
267 granules in multiple tissues in ISIS 416858-treated animals was an expected histologic change for a
268 uced pulmonary arterial pressure in MGCD0103-treated animals was associated with blunted pulmonary ar
269 ficant (p < 0.05) demyelination in cuprizone-treated animals was found according to both LFB staining
270 in recombinant tissue-plasminogen activator-treated animals was in the same order as in saline-treat
271 ocomotor performance of previously cuprizone-treated animals was monitored using the motor skill sequ
272 VH3 clan IgG from S. aureus-infected or SpA-treated animals was not pathogen-specific, suggesting th
274 le intravenous dose of diclofenac (2 mg/kg) (treated animals) was given, and after 20 min, (99m)Tc-MA
279 result, it was found that medicated and non-treated animals were clearly clustered in distinct group
280 e due to suppression of IFN-gamma, linezolid-treated animals were given intranasal instillations of r
283 epatic lymphocytes from IFN-alpha- and IL-15-treated animals were transferred to new HBV carriers, pa
284 production compared to the control antibody treated animals, whereas a change in gob5 gene expressio
285 and diastolic strain only in the combination-treated animals, which also exhibited increased cardiomy
286 s remained elevated within the BAL fluids of treated animals, which was consistent with the fungal bu
287 e production in H2 R-deficient or famotidine-treated animals, while dimaprit dampened the lung iNKT c
288 ed the intestinal microbiota of streptomycin-treated animals, while vancomycin promoted the expansion
289 further examine GABA(A) function on NPCs, we treated animals with a GABA(A) allosteric agonist, pento
290 Survival was significantly improved in Cpt-treated animals with a survival benefit visible as soon
292 We included 4 experimental groups: vehicle-treated animals with extraction of healthy teeth or teet
293 eth or teeth with ligature-induced EP and ZA-treated animals with extraction of healthy teeth or teet
294 onatal C57BL/6 or C3H mice with H. pylori or treated animals with H. pylori components (bacterial lys
295 Control animals were injected with water and treated animals with rimcazole (26 mg/kg) in water.
296 bleeding on the surface of lungs of anti-PR3 treated animals, with histological evidence of vasculiti
297 mpared with 17% (n = 30) in the anti-Vbeta13-treated animals, with minimal islet pathology in nondiab
299 in HCV viremia was observed in one of three treated animals without apparent hepatocellular injury.
300 uctions ranging from 46 to 55% in 38% of the treated animals without causing any toxic side effects.
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。